Eli Lilly agreed to buy Houston-based CrossBridge Bio for up to $300 million to expand its antibody-drug conjugate (ADC) portfolio. The acquisition adds CrossBridge’s dual-payload ADC approach and its preclinical TROP2-directed candidate CBB-120, with plans to file to start human trials this year. For Lilly, the deal builds on recent internal ADC momentum, including prior acquisitions of ADC-focused startups Emergence Therapeutics and Mablink Bioscience. CrossBridge’s platform is designed to improve therapeutic index versus single-payload ADCs, aiming to increase response duration and reduce resistance, though clinical efficacy data are not yet available.